Panacea Biotec Ltd

Financial results and audit

• Standalone and Consolidated unaudited results for quarter ended 30 Jun 2026 approved.
• Limited review by statutory auditors completed; results approved.
• Revenue from operations: Standalone 13,471 lakh; Consolidated 19,957 lakh.
• Net profit after tax: Standalone 139 lakh; Consolidated 220 lakh.
• Going concern: standalone retained earnings negative; group retained earnings positive.
• Consolidated exceptional income: 274 lakh from Apotex settlement.
• Deferred consideration balance as at 31 Mar 2026: 1,019 lakh.
• Balance deferred consideration of 745 lakh to be recognised later.

AGM and governance actions

• 42nd AGM scheduled for 29 Sep 2026 at 11:30 AM via Video Conferencing.
• Register of Members and Share Transfer Books closed 25-29 Sep 2026 (inclusive).
• Scrutinizer for e-Voting: Debabrata Deb Nath.

Key financial items and disclosures

• Auditors: Suresh Surana & Associates LLP reviewed standalone and consolidated results.
• Segment information disclosed in consolidated results (Vaccines and Formulations).
• Standalone segment revenues: Vaccines 13,467 lakh; Formulations 6,490 lakh.
• Consolidated segment pre-tax: Vaccines 747 lakh; Formulations -390 lakh; subtotal 357.
• Notes: results prepared under Ind AS; published on company and stock exchange websites.

Legal actions on Mohali awards

• Four awards dated March 19, 2026 from Mohali Industrial Tribunal.
• On July 16, 2026, Panacea filed appeal against the remaining fourth Mohali award.
• High Court heard three appeals and issued an interim no-coercive-order.
• Awards include set aside transfer of 23 workers and full back wages.
• Awards also cover wage revision and 50% back wages for reinstated workers.
• Company believes awards are challengeable; expects no material adverse impact.

Transaction details

• Inter-se transfer among promoters by gift, no consideration, under Reg 10(7)/10(1)(a)(ii).
• Acquirer: Rajesh Jain HUF; Seller: Dr. Rajesh Jain; promoter group relationship.
• Date of acquisition: 12/06/2026; submission date: 08/07/2026.
• Shares acquired: 200,000; post-acquisition holding 0.09% of Panacea Biotec.

Shareholding impact

• Seller's pre-acquisition holding: 30,217,312 shares (13.57%).
• Seller's post-acquisition holding: 30,017,312 shares (13.48%).
• Acquirer's post-acquisition holding: 200,000 shares (0.09%).
• Promoter group status remains; no control change.

Regulatory compliance

• Exemption under Regulation 10(1)(a)(ii) complied; report submitted within 21 working days.
• Report filed with stock exchanges at least 4 working days prior.
• Promoters named in shareholding pattern; 60-day VWAP/valuation not applicable.

Notes / special context

• Gift transaction; no consideration; inter-se transfer within promoter group.
• Acquirer total shareholding post-acquisition nominal at 0.09%.

Tribunal awards appeals

• Panacea Biotec filed appeals on July 6, 2026 against three of four Mohali tribunal awards.
• Appeals target four awards dated March 19, 2026, received April 9, 2026.
• Awards set aside transfer of 23 workers and granted full back wages.
• Awarded 50% back wages on reinstatement for workers.
• Company expects no material adverse financial or operational impact.
• Period covered: awards applicable from 2014 onwards.
• Awaiting final outcome of remaining award appeal.
• Update filed under SEBI LODR; awaiting court hearing for remaining award.

Dematerialisation actions confirmed

• Dematerialisation requests processed; physical certificates mutilated and cancelled within ~5 days.
• Securities dematerialised have been listed on the stock exchange where the earlier issued securities are listed.
• Depository name substituted as registered owner in records within ~5 days.

Share dematerialisation status

• No shares dematerialised during June 2026.
• NSDL dematerialised shares as of 30 June 2026: 52,478,317.
• CDSL dematerialised shares as of 30 June 2026: 8,627,209.
• Total dematerialised shares as of 30 June 2026: 61,105,526.